Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation reports developments across medical technology, patient monitoring and connected care. Company updates commonly center on Masimo SET pulse oximetry, noninvasive measurements, sensors, patient monitors, Masimo Hospital Automation and Masimo SafetyNet platforms, and telehealth or telemonitoring applications used in hospital and care settings.
Recurring MASI news also includes clinical evidence for monitoring performance, operating and financial results, non-GAAP financial materials, material agreements, shareholder voting matters, governance updates and capital-structure disclosures. The company’s public updates reflect its focus on healthcare monitoring technologies following the completed disposition of its consumer audio business.
Masimo (NASDAQ: MASI) has announced that Dr. Augusto Sola, Vice President of Medical Affairs for Neonatology, has received the prestigious 2020 Pioneer Award from the American Academy of Pediatrics (AAP). This award honors Dr. Sola's significant contributions in neonatology, particularly through the use of Masimo SET® technology, which has greatly improved health outcomes for newborns. His work has been instrumental in reducing neonatal blindness and enhancing understanding of neonatal care.
Masimo (NASDAQ: MASI) presented findings from a retrospective study at ANESTHESIOLOGY 2020, demonstrating that the Oxygen Reserve Index (ORi) could effectively predict postoperative oxygen therapy needs in children with obstructive sleep apnea syndrome (OSAS) undergoing tonsillectomy. The study involved 45 pediatric patients, revealing that those requiring therapy had lower mean ORi and SpO2 values (0.28 and 93%, respectively) compared to those who did not (0.64 and 97%). ORi's sensitivity and specificity for predicting the necessity of therapy were calculated at 0.815 and 0.931, respectively. Note that ORi is not FDA-cleared and is unavailable in the U.S.
Masimo Corporation (Nasdaq: MASI) announced preliminary financial results for Q3 2020, projecting product revenue between $274 million and $278 million, representing a growth of 19.7% to 21.4% year-over-year. For the full year 2020, Masimo expects product revenue to be between $1,124 million and $1,128 million, reflecting a growth of 20.0% to 20.5% compared to 2019. A conference call is scheduled for October 27, 2020, to discuss complete financial results and guidance.
Masimo (NASDAQ: MASI) has launched the Radius Tº™ Continuous Thermometer, a wearable device that continuously monitors body temperature and sends data to a smartphone app. This innovation aims to enhance patient care by providing real-time temperature trends without interrupting daily activities, such as sleep. The Radius Tº sensor offers laboratory-accurate measurements within ±0.1ºC and is designed for use in various age groups. While not FDA 510(k) cleared, it is CE marked and marketed under the FDA’s COVID-19 enforcement policy.
Masimo (NASDAQ: MASI) has received FDA clearance for its new Rad-G Pulse Oximeter, a portable device that offers advanced pulse oximetry and vital sign monitoring capabilities. This handheld device is designed for both adults and children, featuring a long-lasting rechargeable battery and a direct-connect sensor. With a robust design, the Rad-G is suitable for varied environments, including outpatient services and emergency scenarios. The device includes continuous monitoring capabilities and is powered by Masimo's proven SET technology, widely used in hospitals for accurate patient assessments.